BACKGROUND: Annual vaccination against seasonal influenza viruses is recommended for school-age children in some countries. There are limited data on the immunogenicity and efficacy of repeated influenza vaccinations. METHODS: In a randomized controlled trial, we administered seasonal trivalent inactivated influenza vaccine (TIV) or placebo to 64 children 6-15 years of age in two consecutive years and explored their humoral antibody responses. RESULTS: Receipt of TIV in the first year was associated with lower antibody titer rises in the second year to seasonal influenza A(H1N1) and A(H3N2) strains for which the vaccine strains remained unchanged. Antibody response to a different influenza B strain in the second year was unaffected by receipt of TIV in the first year. Children who received TIV in both years showed higher antibody titers against pandemic A(H1N1) which was not included in either TIV. CONCLUSIONS: Results from our study suggest that humoral antibody response to TIV may be lower in children receiving repeated vaccination, but receipt of TIV induced seroprotection in most subjects. Our study was underpowered to explore whether differences in immunogenicity translated to differences in vaccine efficacy.
RCT Entities:
BACKGROUND: Annual vaccination against seasonal influenza viruses is recommended for school-age children in some countries. There are limited data on the immunogenicity and efficacy of repeated influenza vaccinations. METHODS: In a randomized controlled trial, we administered seasonal trivalent inactivated influenza vaccine (TIV) or placebo to 64 children 6-15 years of age in two consecutive years and explored their humoral antibody responses. RESULTS: Receipt of TIV in the first year was associated with lower antibody titer rises in the second year to seasonal influenza A(H1N1) and A(H3N2) strains for which the vaccine strains remained unchanged. Antibody response to a different influenza B strain in the second year was unaffected by receipt of TIV in the first year. Children who received TIV in both years showed higher antibody titers against pandemic A(H1N1) which was not included in either TIV. CONCLUSIONS: Results from our study suggest that humoral antibody response to TIV may be lower in children receiving repeated vaccination, but receipt of TIV induced seroprotection in most subjects. Our study was underpowered to explore whether differences in immunogenicity translated to differences in vaccine efficacy.
Authors: Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: Alenka M Zeman; Tyson H Holmes; Shaye Stamatis; Wenwei Tu; Xiao-Song He; Nancy Bouvier; George Kemble; Harry B Greenberg; David B Lewis; Ann M Arvin; Cornelia L Dekker Journal: Pediatr Infect Dis J Date: 2007-02 Impact factor: 2.129
Authors: Joshua G Petrie; Suzanne E Ohmit; Emileigh Johnson; Rachel T Cross; Arnold S Monto Journal: J Infect Dis Date: 2011-03-04 Impact factor: 5.226
Authors: N Baumgarth; O C Herman; G C Jager; L Brown; L A Herzenberg; L A Herzenberg Journal: Proc Natl Acad Sci U S A Date: 1999-03-02 Impact factor: 11.205
Authors: Gabriel M Leung; Joseph S M Peiris; Benjamin J Cowling; Kwok Hung Chan; Vicky J Fang; Lincoln L H Lau; Hau Chi So; Rita O P Fung; Edward S K Ma; Alfred S K Kwong; Chi-Wai Chan; Wendy W S Tsui; Ho-Yin Ngai; Daniel W S Chu; Paco W Y Lee; Ming-Chee Chiu Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: Benjamin J Cowling; Sophia Ng; Edward S K Ma; Vicky J Fang; Hau Chi So; Winnie Wai; Calvin K Y Cheng; Jessica Y Wong; Kwok-Hung Chan; Dennis K M Ip; Susan S Chiu; J S Malik Peiris; Gabriel M Leung Journal: Clin Infect Dis Date: 2012-06-05 Impact factor: 9.079
Authors: Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg Journal: PLoS One Date: 2008-08-20 Impact factor: 3.240
Authors: Rafaella F Q Grenfell; Nathalie B F Almeida; Priscilla S Filgueiras; Camila A Corsini; Sarah V C Gomes; Daniel A P de Miranda; Adelina J Lourenço; Olindo A Martins-Filho; Jaquelline G de Oliveira; Andrea Teixeira-Carvalho; Guilherme R F Campos; Mauricio L Nogueira; Pedro Augusto Alves; Gabriel R Fernandes; Leda R Castilho; Tulio M Lima; Daniel P B de Abreu; Renata G F Alvim; Thaís Bárbara de S Silva; Wander de J Jeremias; Dayane A Otta; Ana Carolina Campi-Azevedo Journal: Front Immunol Date: 2022-06-09 Impact factor: 8.786
Authors: Cuiling Xu; Kwok-Hung Chan; Tim K Tsang; Vicky J Fang; Rita O P Fung; Dennis K M Ip; Simon Cauchemez; Gabriel M Leung; J S Malik Peiris; Benjamin J Cowling Journal: Am J Epidemiol Date: 2015-09-22 Impact factor: 4.897
Authors: G Freeman; S Ng; R A P M Perera; V J Fang; D K M Ip; G M Leung; J S M Peiris; B J Cowling Journal: Epidemiol Infect Date: 2014-05-01 Impact factor: 4.434
Authors: Huong Q McLean; Jennifer P King; Pamela Talley; Brendan Flannery; Sarah Spencer; Min Z Levine; Thomas C Friedrich; Edward A Belongia Journal: J Pediatric Infect Dis Soc Date: 2020-04-30 Impact factor: 3.164
Authors: Sophia Ng; Dennis K M Ip; Vicky J Fang; Kwok-Hung Chan; Susan S Chiu; Gabriel M Leung; J S Malik Peiris; Benjamin J Cowling Journal: PLoS One Date: 2013-03-12 Impact factor: 3.240